PubMed Health⌕ Search

Biomedical subjects

E M Díaz Diego

Publications and source records attributed to E M Díaz Diego.

6 recordsLinked to original sources
PubMed1996

Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.

The aim of this work was to evaluate the response of different biochemical bone markers to tiludronate administration in Paget's disease of bone. Ten patients (five men and five women), 56-77 years old (67 +/- 6.5), were treated for 3 months with tiludronate tablets (400 mg/day). Bone formation markers: alkaline phosphatase (AP), bone alkaline phosphatase (bAP), osteocalcin (BGP), and procollagen I carboxyterminal propeptide (PICP) in serum; and bone resorption markers: serum cross-linked carboxyterminal telopeptides of type I collagen (ICTP), urinary hydroxyproline/creatinine (Hyp/Cr), pyridinoline/Cr (Pyr/Cr), and alpha-1 collagen chain products degradation (CrossLaps) were assessed. Samples were taken before and at monthly intervals for 3 months after treatment began. The results of the present work show that serum AP and bAP are sensitive and reliable biochemical markers of bone formation in the follow-up of tiludronate in this disease. Serum PICP shows less sensitivity than serum AP, and serum BGP is not indicated as biochemical marker in these types of studies. Urinary hydroxyproline seems to be the most reliable biochemical marker of bone resorption. More studies should be performed with urinary Pyr and CrossLaps determinations. Serum ICTP is not adequate for the follow-up of tiludronate treatment in Paget's disease of bone.

Administration, Oral↗
PubMed1995

Lack of correlation between levels of osteocalcin and bone alkaline phosphatase in healthy control and postmenopausal osteoporotic women.

The determination of bone alkaline phosphatase (bAP) by IRMA and the measure of intact osteocalcin (BGP) and/or different fragments by IRMA and/or RIA are new commercially available methods for the evaluation of osteoblast activity. The aim of this work was to study the possible correlation among serum bAP and levels of BGP measured by two different methods: an IRMA which only detects intact-BGP and a RIA which detects intact-BGP and carboxyterminal fragments (C-terminal BGP) in healthy post-menopausal control women and in a group of patients with post-menopausal osteoporosis. Serum samples from 42 consecutive osteoporotic postmenopausal women, aged 62 +/- 11 years, between 39-76, and 14 control women age matched, were drawn after an overnight fasting. Levels of total alkaline phosphatase (AP), bAP, intact BGP, and intact BGP and carboxy terminal fragments were measured. In both groups we found a significant linear correlation between the levels of AP and bAP (r = 0.79, p < 0.001) and intact-BGP and C-terminal BGP (r = 0.97, p < 0.001), but surprisingly we did not find a significant linear correlation between AP or bAP levels and BGP measured in any of the two methods. These results suggest that AP release from osteoblast vesicles and BGP synthesis in these cells are not necessarily simultaneous, reflecting different stages of osteoblast activity.

Adult↗
PubMed1994

Serum concentrations of carboxyterminal cross-linked telopeptide of type I collagen (ICTP), serum tartrate resistant acid phosphatase, and serum levels of intact parathyroid hormone in parathyroid hyperfunction.

We have studied the levels of a new biochemical marker of bone resorption, carboxyterminal cross-linked telopeptide of type I collagen (ICTP), in 26 healthy control subjects, 15 patients with primary hyperparathyroidism (PHPT) and 17 patients with secondary hyperparathyroidism (secondary HPT). Levels of ICTP in PHPT and secondary HPT have been correlated with those of serum tartrate resistant acid phosphatase (TRAP), another biochemical marker of bone turnover, and with serum levels of intact parathyroid hormone (iPTH). The ICTP levels of the control group were 2.07 +/- 0.58 micrograms l-1, n = 26, range 1.3-3.2. They were independent of sex and age in the studied age range (30-62 years). The ICTP levels of PHPT patients were 3.5 +/- 3.5 micrograms l-1, mean +/- SD, range 0.5-12.2 micrograms l-1, significantly higher than those of control subjects (p < 0.05). We found a significant linear correlation between values of ICTP and iPTH levels (p < 0.01), between values of ICTP and serum activity of TRAP (p < 0.01) and between iPTH and TRAP levels (p < 0.01) in patients with PHPT. The ICTP levels in patients with secondary HPT were higher than those of patients with PHPT, 46 +/- 37 micrograms l-1, range 12-167 micrograms l-1 (p < 0.001) due to the impaired renal clearance of this peptide. We did not find a significant linear correlation between values of ICTP and iPTH levels in the serum of patients with secondary HPT, although we found a significant correlation between levels of ICTP and levels of TRAP, both biochemical markers of bone turnover.(ABSTRACT TRUNCATED AT 250 WORDS)

Acid Phosphatase↗
PubMed1994

Six osteocalcin assays compared.

We evaluated comparatively six commercially available osteocalcin kits: ELSA-OST-NAT IRMA (CIS), ELSA-Osteo IRMA (CIS), Osteocalcin IRMA (Nichols), OSTK-PR RIA (CIS), OSCA Test Osteocalcin RIA (Henning), and Osteocalcin RIA (Nichols). All of them presented acceptable values of variance, sensitivity, and serial dilutions. However, only the ELSA-OST-NAT, ELSA-Osteo, and OSCA Test kits had analytical recoveries near 100% for added purified human osteocalcin; the other assays showed important differences in standardization. After treating samples with antibody against amino acids 43-49 of human osteocalcin, only the ELSA-OST-NAT IRMA detected no residual osteocalcin. Stability of serum values at room temperature and at 4 degrees C is good in the ELSA-Osteo and Osteocalcin IRMAs and in the Henning RIA if serum samples are collected in special tubes available with the kit. Differences in stability and after antibody treatment can be due to the degradation of intact osteocalcin molecules in serum and to osteocalcin fragments detected by assays. Results by different assays were well correlated for samples from controls and postmenopausal osteoporotic women but not for patients with impaired renal function or Paget disease of bone, probably because of osteocalcin fragments accumulated in serum of these patients and differences in specificity of the assays.

Antibody Specificity↗
PubMed1993

Usefulness of biochemical markers of bone turnover in rats after clodronate administration.

Dichloromethylene bisphosphonate (clodronate), an inhibitor of bone resorption, has been administered subcutaneously (1.25 mg/day, 3 consecutive days) to control male albino Wistar rats (n = 8). Variations in the levels of serum alkaline phosphatase (AP) and osteocalcin (BGP), biochemical markers of bone formation, and in urinary hydroxyproline (OH-Prol) and serum tartrate-resistant acid phosphatase (TRAP), markers of bone resorption, have been analyzed. A significant decrease was observed in OH-Prol/creatinine and TRAP. We found a positive correlation between the percentage of decrease, with respect to basal values, of TRAP and OH-Prol/creatinine (p < 0.05). These results suggest that TRAP could be a useful marker to evaluate the changes of bone resorption induced by bisphosphonates in the rat together with the classical marker OH-Prol. A significant decrease was observed in AP. BGP also decreased significantly, but the decrease was relatively small compared to the coefficient of variation of the method. We suggest the preferential use of AP determination, instead of BGP, in the study of the effects produced by bisphosphonates on bone formation in rats, if hepatic function is maintained.

Acid Phosphatase↗